Oncology is a big investment target – here’s what investors care about
Me-too drugs and ill-defined AI are less interesting than unmet need and AI with supporting evidence.
Pharma is making inroads into digital health, albeit slowly
Panelists highlight Roche's acquisition of Flatiron Health in February and use of AI/ML in drug development.
presented by
5 Major Trends Emerging in Healthcare Benefits in 2025
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
US slower than Europe, emerging markets in liquid biopsy adoption
Blood-based cancer tests have market, but more evidence may be needed to verify validity and utility.